We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer.
- Authors
Madan, Ravi A.; Karzai, Fatima H.; Al Harthy, Munjid; Petrylak, Daniel P.; Kim, Joseph W.; Arlen, Philip M.; Rosner, Inger; Theoret, Marc R.; Cordes, Lisa; Bilusic, Marijo; Peer, Cody J.; Dawson, Nancy A.; Couvillon, Anna; Hankin, Amy; Williams, Moniquea; Chun, Guin; Owens, Helen; Marte, Jennifer L.; Lee, Min‐Jung; Tomita, Yusuke
- Abstract
Objective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. Patients and Methods: This was a phase 1/2 multicentre study in patients with metastatic castration‐resistant prostate cancer (mCRPC). Docetaxel (75 mg/m2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone. Results: A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. Dose‐limiting toxicities were neutropenic fever and palmar‐plantar erythrodysesthesia, and there was one death attributable to a thromboembolic event. In addition, grade 3 or 4 myelosuppression, hypophosphataemia and neuropathy were seen in three or more patients. In the phase 1 study, the median time to progression (TTP) and overall survival (OS) time were 13.6 and 16.3 months, respectively. In the phase 2 study, which was terminated early because of poor accrual, the median TTP and OS favoured the combination (n = 13) compared to docetaxel/prednisone alone (n = 12; 21.0 vs 6.6 months; P = 0.035 and 23.8 vs 15.6 months; P = 0.072, respectively). Conclusion: Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy.
- Subjects
CASTRATION-resistant prostate cancer; DOCETAXEL; HAND-foot syndrome; PREDNISONE; DRUG efficacy
- Publication
BJU International, 2021, Vol 127, Issue 4, p435
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.15227